Investigation of satisfaction and efficacy after switching from daily DPP-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -prospective observational study-

Investigation of satisfaction and efficacy after switching from daily DPP-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -prospective observational study- - Study for the satisfaction and efficacy of trelagliptin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022858

Enrollment

Registered

2016-06-24

Start date

2016-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Keeping daily DPP-4 inhibitors Switching from daily DPP-4 inhibitors to trelagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes who have been taking standard dose of daily DPP-4 inhibitors(Sitagliptin 50mg/Vildagliptin 100mg/Alogliptin 25mg/Linagliptin 5mg/Teneligliptin 20mg/Anagliptin 200mg/Saxagliptin 5mg)for more than 12 weeks. 2)Age:20 to 80 years old 3)The number of medication is less than six other than DPP-4 inhibitor 4)Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patient with malignant tumor 2)Pregnancy, nursing woman or possibly pregnant woman 3)Patients with severe infection, pre or post operation, severe trauma 4)Patients who are taking kinds of steroid 5)Patients with severe liver dysfunction(AST,ALT>100U/L) 6) Type 1 diabetes mellitus 7) Patients with hypersensitivity to study drugs on this study 8)Patients who can not do diet and exercise therapy 9)Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
DTSQ(Diabetes Treatment Satisfaction Questionnaire)	—

Secondary

Measure	Time frame
DTR-QOL(Diabetes Therapy Related Quality of life) HbA1c Plasma glucose Weight Frequency of hypoglycemia Stratified analysis(contributing factors, etc)using results of the questionnaire.	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026